Literature DB >> 8076633

Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.

E Sancho1, D W Tonge, R C Hockney, N A Booth.   

Abstract

Plasminogen-activator inhibitor type 1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator, is an unusual member of the serine protease inhibitor (serpin) superfamily in that it spontaneously converts to a latent form lacking activity. This latent form can be reactivated by denaturation and refolding, but the activation is usually incomplete and often leads to aggregation of the protein. In this study we have developed a high-level expression system that leads to the accumulation of PAI-1 at 30-50% total microbial protein. We have developed a single-step purification protocol which can be completed in a few hours, yielding approximately 20 mg purified recombinant PAI-1/litre culture. The purified PAI-1 was 80-100% active and was stable upon incubation at 37 degrees C with a half-life of approximately 48 h. At 20 degrees C, PAI-1 activity was stable for a week and at 4 degrees C it retained its activity completely for up to two months. Freezing caused significant loss of activity. The stability of PAI-1 activity was found to be dependent on pH and ionic strength, being most stable at pH 5.6 and at an ionic strength of 1 M salt. We show that by a combination of high-level expression and rapid purification under optimum conditions, it is possible to produce active and stable PAI-1 in high yield.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8076633     DOI: 10.1111/j.1432-1033.1994.tb20003.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

Authors:  Christian Boudier; Ann Gils; Paul J Declerck; Joseph G Bieth
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

2.  Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC).

Authors:  S Rosenblatt; J A Bassuk; C E Alpers; E H Sage; R Timpl; K T Preissner
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

3.  Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase.

Authors:  Victor Garcia; Eon Joo Park; Mauro Siragusa; Florian Frohlich; Mohammad Mahfuzul Haque; Jonathan V Pascale; Katherine R Heberlein; Brant E Isakson; Dennis J Stuehr; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-16       Impact factor: 11.205

4.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

Review 5.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

6.  The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays.

Authors:  Marlien Pieters; Sunelle A Barnard; Du Toit Loots; Dingeman C Rijken
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

7.  Conformational preludes to the latency transition in PAI-1 as determined by atomistic computer simulations and hydrogen/deuterium-exchange mass spectrometry.

Authors:  Michael Petersen; Jeppe B Madsen; Thomas J D Jørgensen; Morten B Trelle
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

8.  Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.

Authors:  Richard G Jung; Pouya Motazedian; F Daniel Ramirez; Trevor Simard; Pietro Di Santo; Sarah Visintini; Mohammad Ali Faraz; Alisha Labinaz; Young Jung; Benjamin Hibbert
Journal:  Thromb J       Date:  2018-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.